Phase 4 N=128 Protocolized Initiation of Clonidine to Prevent Dexmedetomidine Withdrawal
Withdrawal; Therapeutic Substance
Primary: Number of Participants With Withdrawal — 33; 10 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=21 Open Label Study of MDMA-assisted Psychotherapy for Treatment of PTSD With Optional fMRI Sub-Study
PTSD
Primary: Change in CAPS-5 Total Severity Score — -13.95 score on a scale
N/A N=10 Dynamic Neural Mechanisms of Brexanolone-induced Antidepressant Effects in Postpartum Depression
Postpartum Depression
Primary: Number of Successfully Analyzed EEG Recordings — 49 EEG recordings
N/A N=7 TMS for Improving Response Inhibition in Adolescents With OCD
Obsessive-Compulsive Disorder
Primary: Change in Response Time on Stop Trials of the Stop Signal Task — -26.2; -31.7 milliseconds
Phase 2 N=158 Anastrozole and Letrozole After Surgery for the Treatment of Stage I-III Breast Cancer
Anatomic Stage I Breast Cancer AJCC v8 · Anatomic Stage IA Breast Cancer AJCC v8 · Anatomic Stage IB Breast Cancer AJCC v8
Primary: Percentage of Participants With Adequate Estrogen Suppression After 8 Weeks of Adjuvant Anastrozole 10 mg Daily — 76.0 percentage of participants
N/A N=37 tDCS Intervention in Primary Progressive Aphasia
Primary Progressive Aphasia · MCI · FTD
Primary: Absolute Percent Change in Written Naming (Trained Items) — 39.4; 28.4; 33.1; 20.0 absolute percent change
Phase 2 N=104 A 12-Week Placebo-Controlled Study to Investigate the Efficacy, Safety, and Tolerability of RO7017773 in Participants Aged 15-45 Years With Autism Spectrum Disorder (ASD)
Autism Spectrum Disorder (ASD)
Primary: Change From Baseline to Week 12 in the Adaptive Behavior Composite (ABC) Score of the Vineland Adaptive Behavior Scales, Third Edition (Vineland-3) — 3.250; 2.819; 2.807…
N/A N=63 Prospective Research in Infants With Mild Encephalopathy
Hypoxic-Ischemic Encephalopathy · Brain Injury · Neonatal Seizure
Primary: Percentage of Infants With Evidence of Neurological Dysfunction, Brain Injury and/or Abnormality. — 28 Participants
Early Phase 1 N=16 Neoadjuvant Imiquimod Immunotherapy for Oral Cancer
Oral Squamous Cell Carcinoma
Primary: Number of Participants With 50% Reduction in Tumor Cell Count and Major Pathologic Response — 9; 6 Participants
Phase 1 N=66 A Study of Multiple Doses of HM15211(Efocipegtrutide) in Obese Subjects With NAFLD
NAFLD
Primary: Number of Participants With Adverse Events — 7; 9; 9; 8 Participants
N/A N=35 Social Determinants of Health Screening and Interventions
Social Determinants of Health · Patient Satisfaction · Quality of Life
Primary: Correlation Co-efficient Between Patient Satisfaction Assessed Using HCAHPS and the Domains at Risk — -0.061 correlation coefficient — p=.727
N/A N=1,821 PCV13 Effectiveness Study Against Hospitalised VT Pneumococcal CAP in Adults 60 Years and Older
Community Acquired Pneumonia (CAP)
Primary: Number of Participants Categorized as Cases and Controls to Determine Vaccine Effectiveness (VE) of PCV13 Against Hospitalized VT CAP: Overall — 105; 1407 Participants…
N/A N=146 Analyses of Anemia in Very Low Birth Weight (VLBW) Infants.
Very Preterm Maturity of Infant · The Risk Factors for Improving the Prognosis of VLBW Infants
Primary: The Incidence of Early Onset Sepsis in VLBW Infants With AOP. — 18; 34; 7; 42 Participants
N/A N=51 Preventing Excessive Weight Gain and Maternal and Infant Fat Accretion
Gestational Weight Gain · Maternal Fat Accretion · Infant Fat Accretion
Primary: Maternal Weight Changes — 70.20; 66.47; 80.12; 75.80 kg
N/A N=20 BP Management System User Acceptance Testing
Hypotension and Shock
Primary: Quantitative Nurse-subject Survey Response — 13; 4; 1; 0 Participants